Oxygen Biotherapeutics, Inc. Share Price Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 60.51L 50Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.9Cr -158.41Cr | Net income 2025 * | -1.8Cr -150.07Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.83
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14/21/14 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/14/04 |
June Almenoff
BRD | Director/Board Member | 67 | 25/21/25 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/21/25 |
1st Jan change | Capi. | |
---|---|---|
+34.01% | 5.11TCr | |
+33.84% | 3.89TCr | |
-8.02% | 3.88TCr | |
-8.98% | 2.67TCr | |
+12.56% | 2.63TCr | |
-19.62% | 1.95TCr | |
+39.18% | 1.36TCr | |
+31.47% | 1.25TCr | |
-3.40% | 1.17TCr |